Abstract Library

#4626 Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Introduction: The efficacy and time to progression (TTP) following peptide receptor radionuclide therapy (PRRT) for pancreatic neuroendocrine tumours varies widely.

Conference:

Presenting Author: Papantoniou D

Authors: Tiensuu Janson E, Fröss-Baron K, Grönberg M, Ziolkowska B,

Keywords: prrt, pancreatic neuroendocrine tumour, predictive model,

#3866 Treatment efficacy in 212 metastatic small intestinal neuroendocrine tumor grade 2 patients

Introduction: Small intestinal neuroendocrine tumors (Si-NET) are frequently studied as a single entity, irrespective of their grade, which is known to influence prognosis.

Conference:

Presenting Author: Papantoniou D

Authors: Papantoniou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K,

Keywords: small intestinal neuroendocrine tumor, grade 2, somatostatin analogues, PRRT, Ki-67, somatostatin-receptor negative,

#3310 Ectopic Cushing’s syndrome: Experience from a tertiary care center

Introduction: Neuroendocrine neoplasms (NENs) causing ectopic Cushing’s syndrome (ECS) are relatively rare and very challenging to treat.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lase I

Authors: Lase I, Grönberg M, Strele I, Kozlovacki G, Norlën O,

Keywords: Ectopic Cushing’s syndrome, ACTH, neuroendocrine, hypercortisolism, multiple hormone secretion, bilateral adrenalectomy,

#3265 Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumors grade 2

Introduction: Multianalytes might be used to monitor small intestinal neuroendocrine tumors (siNETs) Grade 2 in the future, but blood chromogranin A (CgA) and urine 5HIAA are still widely used in clinical praxis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Papantoniou D, Grönberg M, Landerholm K, Welin S, Ziolkowska B,

Keywords: Chromogranin A, 5HIAA, small intestinal neuroendocrine tumor, biomarker, carcinoid, cut-offs,

#2109 Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ali A

Authors: Ali A, Grönberg M, Hjortland G, Grønbæk H, Ladekarl M,

Keywords: chemotherapy, Neuroendocrine Neoplasms, Intravenous, Oral, survival,